February 8th 2021 Immunocore Limited
Exhibit 4.21
February 8th 2021
Immunocore Limited
00 Xxxx Xxxxx
Xxxxxx Xxxx
Xxxxxxxx
Xxxx
XX00 0XX
Xxxxxx Xxxxxxx
Attn: Xx. Xxxxxx Xxxxxx, CEO
Dear Dr. Jallal:
Reference is made to that certain Collaboration and Licence Agreement between Immunocore Limited (“Immunocore”) and GlaxoSmithKline Intellectual Property Development Limited
(“GSK”) dated June 29, 2013, as amended from time to time (the “Agreement”). Terms not defined in this letter have the meanings ascribed to them in the Agreement.
Following from discussions internally at GSK, GSK has decided to terminate the Agreement pursuant to Section 13.2(b), solely with respect to the Initial Target Program related to
the Initial Target (NY-ESO-1) (the “NYESO Program”). Termination of the NYESO Program will be effective 90 Business Days from the date of this notice. We will be in touch shortly to discuss next steps and which of the provisions of Section 13.6 are
applicable to the termination of the NYESO Program.
We are disappointed that the NYESO Program will not continue but remain excited about our remaining Collaboration Program. All terms and conditions of the Agreement not affected
by this notice remain in full force and effect.
|
|
Sincerely,
|
|
|
|
|
|
GlaxoSmithKline Intellectual Property Development Limited
|
/s/ Xxxxxx Xxxxxxx
Xxxxxx Xxxxxxx – Authorized signatory for and behalf of Edinburgh Pharmaceutical Industries Limited
/s/ Xxxx Xxxxxx
Xxxx Xxxxxx – Authorized signatory for and behalf of Glaxo Group Limited
